Athira Pharma Statistics

Total Valuation

Athira Pharma has a market cap or net worth of $20.40 million. The enterprise value is -$46.72 million.

Market Cap	20.40M
Enterprise Value	-46.72M

Important Dates

The next estimated earnings date is Thursday, February 20, 2025, after market close.

Earnings Date	Feb 20, 2025
Ex-Dividend Date	n/a

Share Statistics

Athira Pharma has 38.67 million shares outstanding. The number of shares has increased by 0.98% in one year.

Current Share Class	38.67M
Shares Outstanding	38.67M
Shares Change (YoY)	+0.98%
Shares Change (QoQ)	+0.36%
Owned by Insiders (%)	8.02%
Owned by Institutions (%)	28.25%
Float	27.93M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.36
P/TBV Ratio	0.36
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.95, with a Debt / Equity ratio of 0.02.

Current Ratio	2.95
Quick Ratio	2.54
Debt / Equity	0.02
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -102.87% and return on invested capital (ROIC) is -64.93%.

Return on Equity (ROE)	-102.87%
Return on Assets (ROA)	-51.60%
Return on Capital (ROIC)	-64.93%
Revenue Per Employee	n/a
Profits Per Employee	-$1.63M
Employee Count	67
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -75.07% in the last 52 weeks. The beta is 3.00, so Athira Pharma's price volatility has been higher than the market average.

Beta (5Y)	3.00
52-Week Price Change	-75.07%
50-Day Moving Average	0.59
200-Day Moving Average	1.82
Relative Strength Index (RSI)	40.64
Average Volume (20 Days)	347,666

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-111.85M
Pretax Income	-113.45M
Net Income	-109.22M
EBITDA	-110.88M
EBIT	-111.85M
Earnings Per Share (EPS)	-$2.85

Full Income Statement

Balance Sheet

The company has $68.86 million in cash and $1.31 million in debt, giving a net cash position of $67.54 million or $1.75 per share.

Cash & Cash Equivalents	68.86M
Total Debt	1.31M
Net Cash	67.54M
Net Cash Per Share	$1.75
Equity (Book Value)	57.58M
Book Value Per Share	1.49
Working Capital	54.25M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$97.45 million and capital expenditures -$33,000, giving a free cash flow of -$97.48 million.

Operating Cash Flow	-97.45M
Capital Expenditures	-33,000
Free Cash Flow	-97.48M
FCF Per Share	-$2.52

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Athira Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.98%
Shareholder Yield	-0.98%
Earnings Yield	-524.52%
FCF Yield	-468.14%

Analyst Forecast

The average price target for Athira Pharma is $11.25, which is 2,032.30% higher than the current price. The consensus rating is "Buy".

Price Target	$11.25
Price Target Difference	2,032.30%
Analyst Consensus	Buy
Analyst Count	4
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1